BIOCRYST PHARMACEUTICALS INC
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $874.8M | $450.7M | $331.4M | $270.8M | $157.2M |
| Operating income | $341.0M | -$2.5M | -$103.7M | -$148.4M | -$177.7M |
| Cost of revenue | $19.1M | $12.3M | $4.5M | $6.4M | $7.2M |
| Cash from operations | $347.4M | -$52.0M | -$95.1M | -$161.8M | -$142.2M |
| Capital expenditure | $2.5M | $1.1M | $2.2M | $1.4M | $2.4M |
| Free cash flow | $344.9M | -$53.1M | -$97.3M | -$163.2M | -$144.5M |
| Impairments | $0 | $0 | $1.5M | $0 | $0 |
| Total assets | $514.2M | $490.4M | $517.0M | $550.0M | $588.2M |
| Total liabilities | $633.3M | $966.4M | $972.5M | — | — |
Shares outstanding 254.2M · Free float 96.1%
Annual filing data through FY ended December 31, 2025; float as of July 11, 2026.